{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:22:43Z","timestamp":1792592563959,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T00:00:00Z","timestamp":1696291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T00:00:00Z","timestamp":1696291200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medizinische Hochschule Hannover (MHH)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background and aims<\/jats:title>\n                <jats:p>Hepatitis D virus (HDV) infection causes the most severe form of chronic viral hepatitis. However, it is still unclear to what extent the underlying cirrhosis may contribute to disease progression. The aim of this study was to compare the long-term outcome of HDV infection with HBV monoinfection in a single-center cohort of both non-cirrhotic and cirrhotic patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Method<\/jats:title>\n                <jats:p>We retrospectively studied 175 patients with chronic hepatitis D (CHD) who were followed for at least 6\u00a0months (median of 6.3 (0.6\u201323.6) years). In addition, we selected 175 patients with HBV monoinfection (CHB) who were matched for gender, age, region of origin, HBeAg status, and bilirubin. Liver-related clinical end points were defined as hepatic decompensation (ascites, encephalopathy, variceal bleeding), liver transplantation, HCC, or liver-related death.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Clinical complications developed earlier (4.6 vs. 6.2\u00a0years) and more frequently (35.4% vs. 12.6%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01) in CHD patients. In a multivariate Cox regression, HDV infection was independently associated with the development of end points (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01; HR: 3.0; 95% CI 1.4\u20136.4). However, in cirrhotic patients there were no significant differences between HBV and HDV in the development of end points. Besides, CHB patients with cirrhosis developed more frequently HCC (35.5%) than CHD patients with cirrhosis (18.5%).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our results confirmed that HDV leads to a faster progression to cirrhosis compared to HBV. However, once cirrhosis is present, not HDV but the underlying cirrhosis is the dominate intrinsic risk factor for the development of liver-related end points and for the progression to HCC.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12072-023-10575-0","type":"journal-article","created":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T18:01:59Z","timestamp":1696356119000},"page":"1359-1367","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Clinical long-term outcome of hepatitis D compared to hepatitis B monoinfection"],"prefix":"10.1007","volume":"17","author":[{"given":"Anika","family":"Wranke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Heidrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Deterding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina Luise","family":"Hupa-Breier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janina","family":"Kirschner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Bremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Cornberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2906-0480","authenticated-orcid":false,"given":"Heiner","family":"Wedemeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,3]]},"reference":[{"key":"10575_CR1","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1136\/gutjnl-2020-323888","volume":"70","author":"S Urban","year":"2021","unstructured":"Urban S, Neumann-Haefelin C, Lampertico P. Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease. Gut. 2021;70:1782\u20131794","journal-title":"Gut"},{"key":"10575_CR2","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S2468-1253(18)30056-6","volume":"3","author":"Polaris Observatory Collaborators","year":"2018","unstructured":"Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol 2018;3:383\u2013403","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10575_CR3","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.jhep.2020.04.008","volume":"73","author":"AJ Stockdale","year":"2020","unstructured":"Stockdale AJ, Kreuels B, Henrion MYR, Giorgi E, Kyomuhangi I, de Martel C, et al. The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis. J Hepatol 2020;73:523\u2013532","journal-title":"J Hepatol"},{"key":"10575_CR4","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.jhep.2010.06.008","volume":"53","author":"GA Niro","year":"2010","unstructured":"Niro GA, Smedile A, Ippolito AM, Ciancio A, Fontana R, Olivero A, et al. Outcome of chronic delta hepatitis in Italy: a long-term cohort study. J Hepatol 2010;53:834\u2013840","journal-title":"J Hepatol"},{"key":"10575_CR5","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1111\/j.1365-2893.2010.01324.x","volume":"18","author":"M Buti","year":"2011","unstructured":"Buti M, Homs M, Rodriguez-Frias F, Funalleras G, Jardi R, Sauleda S, et al. Clinical outcome of acute and chronic hepatitis delta over time: a long-term follow-up study. J Viral Hepat 2011;18:434\u2013442","journal-title":"J Viral Hepat"},{"key":"10575_CR6","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/j.jhep.2014.05.041","volume":"61","author":"WS Braga","year":"2014","unstructured":"Braga WS, de Oliveira CM, de Araujo JR, Castilho Mda C, Rocha JM, Gimaque JB, et al. Chronic HDV\/HBV co-infection: predictors of disease stage\u2013a case series of HDV-3 patients. J Hepatol 2014;61:1205\u20131211","journal-title":"J Hepatol"},{"key":"10575_CR7","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1002\/hep.31214","volume":"72","author":"H Kamal","year":"2020","unstructured":"Kamal H, Westman G, Falconer K, Duberg A, Weiland O, Haverinen S, et al. Long-term study of hepatitis Delta virus infection at secondary care centers: the impact of viremia on liver-related outcomes. Hepatology. 2020;72:1177\u20131190","journal-title":"Hepatology"},{"key":"10575_CR8","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.jhep.2020.06.038","volume":"73","author":"D Roulot","year":"2020","unstructured":"Roulot D, Brichler S, Layese R, BenAbdesselam Z, Zoulim F, Thibault V, et al. Origin, HDV genotype and persistent viremia determine outcome and treatment response in patients with chronic hepatitis delta. J Hepatol 2020;73:1046\u20131062","journal-title":"J Hepatol"},{"key":"10575_CR9","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1053\/j.gastro.2009.01.052","volume":"136","author":"R Romeo","year":"2009","unstructured":"Romeo R, Del Ninno E, Rumi M, Russo A, Sangiovanni A, de Franchis R, et al. A 28-year study of the course of hepatitis Delta infection: a risk factor for cirrhosis and hepatocellular carcinoma. Gastroenterology. 2009;136:1629\u20131638","journal-title":"Gastroenterology"},{"key":"10575_CR10","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1136\/gut.46.3.420","volume":"46","author":"G Fattovich","year":"2000","unstructured":"Fattovich G, Giustina G, Christensen E, Pantalena M, Zagni I, Realdi G, et al. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European concerted action on viral hepatitis (Eurohep). Gut. 2000;46:420\u2013426","journal-title":"Gut"},{"key":"10575_CR11","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1111\/apt.15188","volume":"49","author":"G Brancaccio","year":"2019","unstructured":"Brancaccio G, Fasano M, Grossi A, Santantonio TA, Gaeta GB. Clinical outcomes in patients with hepatitis D, cirrhosis and persistent hepatitis B virus replication, and receiving long-term tenofovir or entecavir. Aliment Pharmacol Ther 2019;49:1071\u20131076","journal-title":"Aliment Pharmacol Ther"},{"key":"10575_CR12","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.jhep.2020.02.030","volume":"73","author":"D Alfaiate","year":"2020","unstructured":"Alfaiate D, Cl\u00e9ment S, Gomes D, Goossens N, Negro F. Chronic hepatitis D and hepatocellular carcinoma: a systematic review and meta-analysis of observational studies. J Hepatol 2020;73:533\u2013539","journal-title":"J Hepatol"},{"key":"10575_CR13","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1111\/jvh.13577","volume":"28","author":"H Kamal","year":"2021","unstructured":"Kamal H, Fornes R, Simin J, St\u00e5l P, Duberg A, Brusselaers N, et al. Risk of hepatocellular carcinoma in hepatitis B and D virus co-infected patients: a systematic review and meta-analysis of longitudinal studies. J Viral Hepat 2021;28:1431\u20131442","journal-title":"J Viral Hepat"},{"key":"10575_CR14","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12876-020-1168-9","volume":"20","author":"JH Bockmann","year":"2020","unstructured":"Bockmann JH, Grube M, Hamed V, von Felden J, Landahl J, Wehmeyer M, et al. High rates of cirrhosis and severe clinical events in patients with HBV\/HDV co-infection: longitudinal analysis of a German cohort. BMC Gastroenterol 2020;20:24\u201329","journal-title":"BMC Gastroenterol"},{"key":"10575_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31030","author":"M Cornberg","year":"2019","unstructured":"Cornberg M, Lok AS, Terrault NA, Zoulim F, 2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV treatment endpoints conference. Hepatology. 2019. https:\/\/doi.org\/10.1002\/hep.31030","journal-title":"Hepatology"},{"key":"10575_CR16","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000026571","volume":"100","author":"L Scheller","year":"2021","unstructured":"Scheller L, Hilgard G, Anastasiou O, Dittmer U, Kahraman A, Wedemeyer H, et al. Poor clinical and virological outcome of nucleos(t)ide analogue monotherapy in HBV\/HDV co-infected patients. Medicine (Baltimore). 2021;100: e26571","journal-title":"Medicine (Baltimore)"},{"key":"10575_CR17","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1002\/hep.28876","volume":"65","author":"A Wranke","year":"2017","unstructured":"Wranke A, Serrano BC, Heidrich B, Kirschner J, Bremer B, Lehmann P, et al. Antiviral treatment and liver-related complications in hepatitis delta. Hepatology. 2017;65:414\u2013425","journal-title":"Hepatology"},{"key":"10575_CR18","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1093\/infdis\/jix656","volume":"217","author":"C Yurdaydin","year":"2018","unstructured":"Yurdaydin C, Keskin O, Kalkan C, Karakaya F, Caliskan A, Kabacam G, et al. Interferon treatment duration in patients with chronic delta hepatitis and its effect on the natural course of the disease. J Infect Dis 2018;217:1184\u20131192","journal-title":"J Infect Dis"},{"key":"10575_CR19","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/jvh.13235","volume":"27","author":"BL Da","year":"2020","unstructured":"Da BL, Surana P, Takyar V, Kleiner DE, Heller T, Koh C. Vibration-controlled transient elastography for the detection of cirrhosis in chronic hepatitis D infection. J Viral Hepat 2020;27:428\u2013436","journal-title":"J Viral Hepat"},{"key":"10575_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0092062","volume":"9","author":"R Romeo","year":"2014","unstructured":"Romeo R, Foglieni B, Casazza G, Spreafico M, Colombo M, Prati D. High serum levels of HDV RNA are predictors of cirrhosis and liver cancer in patients with chronic hepatitis delta. PLoS ONE. 2014;9: e92062","journal-title":"PLoS ONE"},{"key":"10575_CR21","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.jhepr.2019.05.001","volume":"1","author":"M Puigveh\u00ed","year":"2019","unstructured":"Puigveh\u00ed M, Moctezuma-Vel\u00e1zquez C, Villanueva A, Llovet JM. The oncogenic role of hepatitis delta virus in hepatocellular carcinoma. JHEP Rep 2019;1:120\u2013130","journal-title":"JHEP Rep"},{"key":"10575_CR22","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1053\/j.gastro.2004.03.017","volume":"126","author":"P Farci","year":"2004","unstructured":"Farci P, Roskams T, Chessa L, Peddis G, Mazzoleni AP, Scioscia R, et al. Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Gastroenterology. 2004;126:1740\u20131749","journal-title":"Gastroenterology"},{"key":"10575_CR23","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1053\/j.gastro.2006.01.035","volume":"130","author":"CW Su","year":"2006","unstructured":"Su CW, Huang YH, Huo TI, Shih HH, Sheen IJ, Chen SW, et al. Genotypes and viremia of hepatitis B and D viruses are associated with outcomes of chronic hepatitis D patients. Gastroenterology. 2006;130:1625\u20131635","journal-title":"Gastroenterology"},{"key":"10575_CR24","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1001\/jama.2014.12627","volume":"312","author":"AJ van der Meer","year":"2014","unstructured":"van der Meer AJ, Wedemeyer H, Feld JJ, Dufour JF, Zeuzem S, Hansen BE, et al. Life expectancy in patients with chronic HCV infection and cirrhosis compared with a general population. JAMA. 2014;312:1927\u20131928","journal-title":"JAMA"},{"key":"10575_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.01.014","author":"M Rizzetto","year":"2021","unstructured":"Rizzetto M, Hamid S, Negro F. The changing context of hepatitis D. J Hepatol 2021. https:\/\/doi.org\/10.1016\/j.jhep.2021.01.014","journal-title":"J Hepatol"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-023-10575-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-023-10575-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-023-10575-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T05:39:25Z","timestamp":1700545165000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-023-10575-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,3]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["10575"],"URL":"https:\/\/doi.org\/10.1007\/s12072-023-10575-0","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,3]]},"assertion":[{"value":"8 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Anika Wranke, Benjamin Heidrich, Katharina Luise Hupa-Breier, Janina Kirschner, and Birgit Bremer declare that they have no conflict of interest. Heiner Wedemeyer serves as clinical trials principal investigator for Abbvie, Altimmune, BMS, Gilead, Janssen, Merck\/MSD, MYR GmbH, Novartis, and Vir Biotechnology, has research grants from Abbvie, Biotest, Gilead, Merck\/MSD, and Roche, and advises or is on the speakers\u2019 bureau for AbbVie, Aligos, Altimmune, Biotest, BMS, BTG, Dicerna, Enanta, Gilead, Janssen, Merck\/MSD, MYR GmbH, Roche, and Vir Biotechnology. Markus Cornberg received honoraria for lectures or consulting from AbbVie, AiCuris, Falk, Gilead, GlaxoSmithKline (GSK), Janssen, Merck\/MSD, Novartis, Roche, Swedish Orphan Biovitrum (SOBI). Katja Deterding received lecture fees and is on the advisory board for Gilead.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the local ethics committee of Hannover Medical School (Hannover, Germany) and performed in accordance with the ethical standards as laid down in the Helsinki Declaration of 1975, as revised in 2008.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was not required from patients included in the study, as all patient information was de-identified and because of the retrospective nature of this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors approved the manuscript for publication.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}